Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

详细信息	查看全文 | 推荐本文 |

• 作者：Jason D. Wright ; Dana Viviano ; Matthew A. Powell ; Randall K. Gibb ; David G. Mutch ; Perry W. Grigsby and Janet S. Rader
• 刊名：Gynecologic Oncology
• 出版年：2006
• 期刊代码：295_00908258
• 类别：med
• 出版时间：November 2006
• 卷：103
• 期：2
• 页码：489-493
• 文件大小：114 K

摘要

Objective.

To report the utility of the monoclonal, anti-vascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with recurrent cervical cancer.

Methods.

A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab combination therapy was performed.

Results.

Six patients were identified. The patients had a median of 3 prior regimens. All of the patients had multisite, metastatic disease. The combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one (17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67%of the subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) patients with stable disease. The median time to progression for the four women who demonstrated clinical benefit was 4.3 months.

Conclusions.

Combination bevacizumab is well tolerated and displayed encouraging anti-tumor activity in heavily pretreated recurrent cervical cancer.